Loading clinical trials...
Loading clinical trials...
Phase II Study to Evaluate the Role of Postoperative Radiotherapy for Low Risk of Locoregional Recurrence Patients With Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer
Conditions
Interventions
PORT
Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
Locations
1
China
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Start Date
November 1, 2016
Primary Completion Date
December 1, 2021
Completion Date
December 1, 2021
Last Updated
November 13, 2020
NCT07339774
NCT07138755
NCT07332000
NCT06719440
NCT07325721
NCT05926765
Lead Sponsor
Shanghai Chest Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions